Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
for
Healthy Volunteers, Influenza
Location: Charlottesville VA, Rochester NY, Coral Gables FL,
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT07779408
Phase1, Phase2, Recruiting
New
Effects of Pork Protein on Recovery Following Simulated Fireground Activity
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
for
Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8,
Location: New Orleans LA, Houston TX
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07551596
Phase2, Recruiting
New
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Location: Ottawa IL, Bloomington IL, Decatur IL, Peru IL,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06948084
Phase2, Recruiting
New
A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)
for
Erythropoietic Protoporphyria (EPP),
Location: Cincinnati OH, Huntington Beach CA
Sponsor: Portal Therapeutics, Inc.
Sex: All
Age: 12+
Code: NCT07820085
Phase2, Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
New
Defining the Ablative Dose for Y-90 TARE
for
HCC - Hepatocellular Carcinoma
Location: Chicago IL
Sponsor: Northwestern University
Sex: All
Age: 18+
Code: NCT07586046
Phase2, Recruiting
New
Level Up! (The Combined and Independent Effects of Exercise Training and Dietary Enhancement on Cardiometabolic Health in Adolescents With Obesity)
for
Obesity
Location: Little Rock AR
Sponsor: Arkansas Children's Hospital Research Institute
Sex: All
Age: 12 - 17
Code: NCT06848478
Recruiting
Active & ResponsiveNew
Within-Subject Comparison of Adipose Tissue Viability Following Liposuction
for
Liposuction
Location: Concord OH, Olympia WA
Sponsor: Apyx Medical
Sex: All
Age: 30 - 65
Code: NCT07820397
Recruiting
New
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
for
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer,
Location: East Brunswick NJ, Fairfax VA, Glendale CA,
Sponsor: SystImmune Inc.
Sex: All
Age: 18+
Code: NCT07625644
Phase3, Recruiting
Active & ResponsiveNew
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
for
Pediatric Tumor of CNS, Pediatric Tumor of Brain,
Location: Orange CA
Sponsor: Neonc Technologies, Inc.
Sex: All
Age: 5 - 18
Code: NCT06357377
Phase1, Recruiting
New
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
for
Primary Biliary Cholangitis
Location: Lakewood Rch FL
Sponsor: Zydus Therapeutics Inc.
Sex: All
Age: 18 - 70+
Code: NCT07424677
Phase3, Recruiting
Active & ResponsiveNew
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
for
Wilson Disease, Wilson's Disease, Wilsons Disease
Location: San Antonio TX
Sponsor: Prime Medicine, Inc.
Sex: All
Age: 12+
Code: NCT07748403
Phase1, Phase2, Recruiting
Active & ResponsiveNew
Voices Illuminating Solutions for Outdoor Workers' Needs and Safety
for
Air Pollution Exposure
Location: Stanford CA
Sponsor: Stanford University
Sex: All
Age: 18+
Code: NCT07713264
Recruiting
New
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
for
Myeloma Multiple
Location: Anchorage AK
Sponsor: Eastern Cooperative Oncology Group
Sex: All
Age: 18+
Code: NCT07085728
Phase2, Recruiting
New
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma